loading
Xortx Therapeutics Inc stock is traded at $1.20, with a volume of 8,881. It is down -6.81% in the last 24 hours and down -36.17% over the past month. XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
See More
Previous Close:
$1.2877
Open:
$1.28
24h Volume:
8,881
Relative Volume:
0.00
Market Cap:
$4.22M
Revenue:
-
Net Income/Loss:
$-6.71M
P/E Ratio:
-2.7397
EPS:
-0.438
Net Cash Flow:
$-8.81M
1W Performance:
-14.29%
1M Performance:
-36.17%
6M Performance:
-52.00%
1Y Performance:
-60.00%
1-Day Range:
Value
$1.19
$1.31
1-Week Range:
Value
$1.19
$1.42
52-Week Range:
Value
$1.09
$7.00

Xortx Therapeutics Inc Stock (XRTX) Company Profile

Name
Name
Xortx Therapeutics Inc
Name
Phone
-
Name
Address
-
Name
Employee
3
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
XRTX's Discussions on Twitter

Compare XRTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
XRTX 1.20 4.22M 0 -6.71M -8.81M -0.438
VRTX 467.79 119.83B 10.63B -479.80M -1.35B 13.33
REGN 761.02 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.78 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.27 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.65 24.08B 3.30B -501.07M 1.03B 11.54

Xortx Therapeutics Inc Stock (XRTX) Latest News

pulisher
Nov 15, 2024

XORTX Therapeutics Inc. Faces Financial Challenges - TipRanks

Nov 15, 2024
pulisher
Nov 15, 2024

XORTX Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024
pulisher
Oct 24, 2024

XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024 - sharewise

Oct 24, 2024
pulisher
Oct 24, 2024

XORTX Highlights Kidney Disease Study at ASN - TipRanks

Oct 24, 2024
pulisher
Oct 18, 2024

XORTX Secures $1.5 Million in Latest Offering - TipRanks

Oct 18, 2024
pulisher
Oct 18, 2024

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire

Oct 18, 2024
pulisher
Oct 17, 2024

XORTX Therapeutics stock falls after pricing $1.5M capital raise - MSN

Oct 17, 2024
pulisher
Oct 17, 2024

XORTX Therapeutics Announces $1.5 Million Offering - TipRanks

Oct 17, 2024
pulisher
Oct 17, 2024

XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire

Oct 17, 2024
pulisher
Oct 16, 2024

The Significance of Moving Averages in XORTX Therapeutics Inc Inc. (XRTX) Price Performance - The InvestChronicle

Oct 16, 2024
pulisher
Oct 09, 2024

XORTX Therapeutics Advances Precision Kidney Care - TipRanks

Oct 09, 2024
pulisher
Oct 09, 2024

XORTX Initiates Precision Medicine Program - GlobeNewswire

Oct 09, 2024
pulisher
Oct 09, 2024

XORTX Therapeutics Inc. Initiates Precision Medicine Program - Marketscreener.com

Oct 09, 2024
pulisher
Oct 08, 2024

S&P 500 Financials [Sector] (SRFI) QuotePress Release - The Globe and Mail

Oct 08, 2024
pulisher
Oct 02, 2024

TSX 60 Shariah Index (TXSI) QuotePress Release - The Globe and Mail

Oct 02, 2024
pulisher
Sep 27, 2024

XORTX Therapeutics (NASDAQ:XRTX) Stock Quotes, Forecast and News Summary - Benzinga

Sep 27, 2024
pulisher
Sep 24, 2024

SEC Form 424B3 filed by XORTX Therapeutics Inc. - Quantisnow

Sep 24, 2024
pulisher
Sep 24, 2024

Form 424B3 XORTX Therapeutics Inc. - StreetInsider.com

Sep 24, 2024
pulisher
Sep 13, 2024

XORTX Therapeutics Shareholders Approve Key Decisions - TipRanks

Sep 13, 2024
pulisher
Sep 13, 2024

XORTX Announces Results of Annual and Special Meeting of Shareholders - GlobeNewswire

Sep 13, 2024
pulisher
Sep 12, 2024

Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail

Sep 12, 2024
pulisher
Sep 12, 2024

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A - GlobeNewswire

Sep 12, 2024
pulisher
Sep 12, 2024

S&P 500 Index (INX) QuotePress Release - The Globe and Mail

Sep 12, 2024
pulisher
Sep 12, 2024

Ford Motor Company (F-N) QuotePress Release - The Globe and Mail

Sep 12, 2024
pulisher
Sep 12, 2024

S&P 500 Communication Services [Sector] (SRTS) QuotePress Release - The Globe and Mail

Sep 12, 2024
pulisher
Sep 12, 2024

Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail

Sep 12, 2024
pulisher
Sep 07, 2024

XORTX Prepares for Shareholders’ Vote on Key Resolutions - TipRanks

Sep 07, 2024
pulisher
Sep 06, 2024

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders - GlobeNewswire

Sep 06, 2024
pulisher
Sep 05, 2024

In the Green: XORTX Therapeutics Inc (XRTX) Closes at 2.38, Up/Down 7.69 from Previous Day - The Dwinnex

Sep 05, 2024
pulisher
Sep 04, 2024

Atara Biotherapeutics (ATRA) Secures Strategic Investments to Advance T-cell Immunotherapy Innovations - BP Journal

Sep 04, 2024
pulisher
Sep 04, 2024

Views of Wall Street’s Leading Experts on XORTX Therapeutics Inc - SETE News

Sep 04, 2024
pulisher
Sep 03, 2024

XORTX Recommended by ISS for Shareholder Approval - TipRanks

Sep 03, 2024
pulisher
Sep 03, 2024

XORTX Therapeutics Inc (XRTX) Stock: The Story of a 52-Week Stock Range - The InvestChronicle

Sep 03, 2024
pulisher
Sep 03, 2024

Independent Proxy Advisory Firm ISS Recommends XORTX - GlobeNewswire

Sep 03, 2024
pulisher
Sep 03, 2024

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders - Yahoo Finance

Sep 03, 2024
pulisher
Aug 31, 2024

Immersion Corp (NASDAQ: IMMR): An Enticing Stock To Watch - Stocks Register

Aug 31, 2024
pulisher
Aug 31, 2024

Comstock Inc (AMEX: LODE) Has Great Upside Potential - Stocks Register

Aug 31, 2024
pulisher
Aug 30, 2024

Value of company developing kidney disease treatments doubles in one day - Kursiv Media

Aug 30, 2024
pulisher
Aug 30, 2024

Pre-market Movers: BNRG, NCNA, PALT, ESTC, LUNR… - RTTNews

Aug 30, 2024
pulisher
Aug 30, 2024

U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.59% - MSN

Aug 30, 2024
pulisher
Aug 29, 2024

XORTX Therapeutics Inc Inc. (XRTX) Price Performance: A Technical Analysis Perspective - The InvestChronicle

Aug 29, 2024
pulisher
Aug 29, 2024

Wall Street-Heavily Traded - WDRB

Aug 29, 2024
pulisher
Aug 29, 2024

XORTX Therapeutics Gain 87% Following Publication of Research Supporting Treatment Pipeline - MarketWatch

Aug 29, 2024
pulisher
Aug 29, 2024

XORTX Therapeutics (XRTX) Stock Up On Major Research Development - Stocks Telegraph

Aug 29, 2024
pulisher
Aug 29, 2024

BioCardia Inc (Nasdaq: BCDA) Achieves Significant FDA Clearance for Morph DNA Steerable Introducer, Paving New Pathways in Cardiovascular Interventions - BP Journal

Aug 29, 2024
pulisher
Aug 29, 2024

XORTX Therapeutics Inc ($XRTX): Pioneering New Treatments for Kidney Disease with a Precision-Medicine Approach - BP Journal

Aug 29, 2024
pulisher
Aug 29, 2024

Nasdaq Surges Over 1%; Best Buy Posts Upbeat Earnings - Benzinga

Aug 29, 2024
pulisher
Aug 29, 2024

XORTX’s Research Reinforces Kidney Disease Treatment Strategy - TipRanks

Aug 29, 2024
pulisher
Aug 29, 2024

XRTX’s valuation metrics: A comprehensive analysis - US Post News

Aug 29, 2024
pulisher
Aug 29, 2024

Dow Jumps Over 100 Points; Nvidia Earnings Top Views - MSN

Aug 29, 2024
pulisher
Aug 29, 2024

Earnings and a potential kidney disease breakthrough - RagingBull

Aug 29, 2024

Xortx Therapeutics Inc Stock (XRTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):